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Abstract: Familial combined hyperlidemia (FCH) is a common metabolic disorder characterized 
by: (a) increase in cholesterolemia and/or triglyceridemia in at least two members of the same 
family, (b) intra-individual and intrafamilial variability of the lipid phenotype, and (c) increased 
risk of premature coronary heart disease (CHD). FCH is very frequent and is one of the most 
common genetic hyperlipidemias in the general population (prevalence estimated: 0.5%–2.0%), 
being the most frequent in patients affected by CHD (10%) and among acute myocardial 
infarction survivors aged less than 60 (11.3%). This percentage increases to 40% when all the 
myocardial infarction survivors are considered without age limits. However, because of the 
peculiar variability of laboratory parameters, and because of the frequent overlapping with 
the features of metabolic syndrome, this serious disease is often not recognized and treated. 
The aim of this review is to deﬁ  ne the main characteristics of the disease in order to simplify 
its detection and early treatment by all physicians by mean of practical guidelines.
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Introduction
The Atherosclerosis and Dysmetabolic Disorders Study Group is an Italian research 
group of highly specialized lipidologists, recognized by the International Atheroscle-
rosis Society, and continuously cooperating with different European and US research 
units. It is historically involved in preclinical and clinical research on genetic disorders 
of lipoprotein metabolism and in publication and promotion of laboratory, diagnostic, 
and therapeutic guidelines in this ﬁ  eld (Lenzi et al 1986; Gaddi et al 2003). In 1994, the 
study group decided to set up a committee of experts on familial combined hyperlipid-
emia (FCH), in order to formulate a coherent description of this disorder, still largely 
unknown to most physicians in spite of its severity and relative prevalence. The latest 
report of this committee was published in 1999 (Gaddi et al 1999). Due to the rapid 
increase in knowledge about the physiopathology of FCH, and to the publication of 
further papers with diagnostic guidelines, based on different criteria, a critical update 
of these guidelines is now necessary.
Deﬁ  nition of FCH
Combining the old and the recent deﬁ  nitions, FCH is now deﬁ  ned as a common meta-
bolic disorder characterized by: (a) increase in cholesterolemia and/or triglyceridemia 
in at least two members of the same family, (b) intra-individual and intrafamilial 
variability of the lipid phenotype, and (c) increased risk of premature coronary heart 
disease (CHD) (Goldstein et al 1973; Sniderman et al 2002).
In this deﬁ  nition other metabolic conditions with similar clinical and labo-
ratory manifestations, such as hyperapobetalipoproteinemia, are considered 
(Kwiterovich 1998). Moreover, in the past FCH was also named “multiple 
phenotype familial hyperlipidemia”, “familial mixed hyperlipidemia”, “familial Vascular Health and Risk Management 2007:3(6) 878
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combined hyperlipoproteinemia”, and “familial combined 
hypercholesterolemia-hypertriglyceridemia”, which can be 
considered as synonyms of FCH.
Structure and metabolism of 
lipoproteins in FCH
The laboratory abnormalities most frequently found in 
FCH are an increase of plasma triglycerides (TG) and or 
cholesterol levels, and a high prevalence of small very-
low-density lipoproteins (VLDLs) and/or LDLs, mainly 
related to an increased plasma level of apolipoprotein B100 
(apo B) (Sniderman et al 2001). Some patients can present 
a decrease in high-density lipoprotein (HDL) cholesterol 
plasma level, often inversely correlated to the TG plasma 
level (Hokanson et al 1993).
VLDLs
An increase in the synthesis of VLDL-apo B (Venkatesan 
et al 1983) is usually present, but the reason why is yet to be 
fully understood. Some authors suggest that this increase is 
related to alterations in the incorporation of fatty acids in the 
TG (Meijssen et al 2002a) and/or alterations of the postpran-
dial metabolism of the VLDLs, with greater conversion to 
small and dense LDLs and/or reduced turnover of the VLDLs 
themselves (Verseyden et al 2002). However, other authors 
showed that VLDL increase in FCH patients is mainly related 
to defects in activity of lipoprotein lipase (Campagna et al 
2002), lecithin:cholesterol acyltransferase (Aouizerat et al 
2002), and/or hepatic lipase (Pihlajamaki et al 2000). On the 
other hand, Evans et al (2007) recently used stable isotope 
techniques combined with tissue-speciﬁ  c measurements in 
adipose tissue and forearm muscle to investigate fatty acid 
handling by these tissues in the fasting and postprandial states 
of FCH patients. They found that the major defect appeared to 
be overproduction of triacylglycerol (TAG) by the liver due 
to decreased fatty acid oxidation, with fatty acids directed to 
TG synthesis, while evidence of decreased lipoprotein lipase 
action or impaired fatty acid re-esteriﬁ  cation in adipose tissue 
was observed.
An impaired postprandial plasma component C3 response 
has been observed in FCH patients, most likely as a result of 
a delayed response by C3, as the precursor for the biologi-
cally active acylation-stimulating protein, acting on free fatty 
acid (FFA) metabolism (Meijssen et al 2002b). Therefore, 
an impaired postprandial C3 response may be associated 
with impaired peripheral postprandial FFA uptake and, 
consequently, lead to increased hepatic FFA ﬂ  ux and VLDL 
overproduction (Meijssen et al 2002a).
In FCH patients, the VLDL TG content is inversely related 
to the LDL-C plasma level: the redistribution of apoB and 
plasma cholesterol could be a key process in development of 
various phenotypes. The plasma apoB and cholesterol in VLDL 
particles, when in abundance, are associated with signiﬁ  cantly 
lower cholesterol levels in the bigger and more buoyant LDL 
particles. This effect is reversible by reducing plasma TG levels 
(by diet, by drugs, and/or by physical activity), which in turn 
may result in redistribution of apoB and TC from the VLDL 
particles to LDL particles (Ayyobi et al 2003).
In a recent study, de Graaf et al (2007) point to high 
remnant-like particles cholesterol (RLP-C) as a potential 
biomarker of FCH. In fact they observed that patients with 
FCH have 2-fold elevated plasma RLP-C levels, which add 
to the atherogenic lipid proﬁ  le and contribute to the increased 
risk for cardiovascular disease (CVD). Plasma RLP-C levels 
above the 90th percentile predicted prevalent CVD, indepen-
dently of non-lipid cardiovascular risk factors (odds ratio 2.18 
[1.02–4.66]) and TG levels (odds ratio 2.35 [1.15–4.83]). 
However, in both FCH patients and controls, RLP-C did not 
provide additional information about prevalent CVD over 
and above non-HDL cholesterol levels).
LDL
There is a predominance of small and dense LDLs (so-called 
atherogenic LDL “B” pattern), poor in cholesterol, and thus 
with a high apo B/cholesterol ratio. The main determinants 
of LDLs size appear to be the TG and HDL-C plasma levels 
(Vakkilainen et al 2002).
The synthesis of LDL-apo B increases due to uncontrolled 
overproduction of apo B (Kissebah et al 1984). No major altera-
tions in the LDL liver catabolic rate have been described: in FCH 
patients, the activity of the LDL receptor (with a high afﬁ  nity for 
apo B100) is normal (Kane et al 1989). The reduction in lipid 
levels after diet and lipid-lowering drugs does not normalize 
the kinetic and structural characteristics of the LDLs, at least 
in a large percentage of patients (Meijssen et al 2002a). Some 
studies suggest that a relative deﬁ  cit of hepatic lipoprotein lipase 
can reduce the liver uptake of apo B to simulate the increased 
synthesis of these apolipoproteins (Williams et al 1991).
Moreover, LDL from FCH patients, irrespective of lipid 
phenotypes, are more susceptible to oxidation in vitro than 
LDL from healthy controls. This increased susceptibility of 
LDL to oxidation in vitro seems to be a consequence of the 
abundance of small dense LDL particles and not to defects 
of antioxidant capacity in FCH (Liu et al 2002). In FCH 
patients with very high LDL-C plasma levels of lipoprotein 
(a) may be high as well (Cicero et al 2003).Vascular Health and Risk Management 2007:3(6) 879
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HDLs
Reduced levels of HDL-C are a frequent ﬁ  nding in FCH 
patients. HDL-C and HDL2 reduction could be due to TG-
enrichment of HDL particles and enhanced hepatic lipase 
(HL), while the role of lipoprotein lipase (LPL) and activities 
of cholesterol ester transfer protein (CETP) and phospholipid 
transfer protein (PLTP) appears to be less evident (Soro et al 
2003). Recent data suggest that HDL-C values are lower in 
subjects with predominantly small and dense LDL and are 
associated with a very high concentration of VLDL-1 (with 
low apo AI and apo E content). LDL pattern is suggested to 
be the main determinant of the phenotype expressed by FCH 
patients (Georgieva et al 2004).
Genetics
FCH was initially suggested to have a dominant monogenic 
mode of inheritance (Austin et al 1990). Later, some authors 
hypothesized a more complex inheritance to explain the 
variability in the lipid phenotype. Pajukanta et al (1998) 
identiﬁ  ed a locus linked to FCH on 1q21-q23 in Finnish 
families with the disease. This region has also been linked 
to FCH in families from other populations (Coon et al 2000; 
Peri et al 2000; Allayee et al 2002) and to type 2 diabetes 
mellitus (Elbein et al 1999; Wiltshire et al 2001). These 
clinical entities have some overlapping phenotypic features, 
raising the possibility that the same gene may underlie the 
obtained linkage results.
Linkage studies and association analysis suggested that 
the association of the newly discovered apo AV gene with 
APOAI/CIII/AIV cluster contributes to FCH transmission in 
a case report of 128 European families (Eichenbaum-Voline 
et al 2004).
Other authors proposed that LDL size in FCH patients 
is a trait inﬂ  uenced by multiple loci located to 9p, 16q, and 
11q (Badzioch et al 2004).
Recently, the gene encoding upstream transcription factor 
1 (USF1) has appeared to be speciﬁ  cally linked to FCH in 
60 extended families with FCH, including 721 genotyped 
individuals, especially males with high TG. USF1 encodes a 
transcription factor known to regulate several genes control-
ling glucose and lipid metabolism. The concept that USF1 
affects the complex lipid phenotype of FCH, and not only one 
lipid trait, is supported by the ﬁ  ndings of the same authors on 
allelic associations of the usf1s1-usf1s2 risk haplotype with 
TG, apo B, TC, and LDL peak particle size (Pajukanta et al 
2004). This ﬁ  nding might explain both the “monogenic”-like 
transmission of the trait and the intra-individual and intra-
family variability of the phenotype.
However, the gene–environment interaction could 
strongly inﬂ  uence the laboratory and clinical features of FCH 
(Stalenhoef 2002; Corella and Ordovas 2005), complicating 
the disease detection by all physicians, and also by special-
ized lipidologists.
Prevalence
FCH is very common and is considered one of the most 
common genetic hyperlipidemias in the general population 
(prevalence estimated: 0.5%–2.0%), being the most common 
in patients affected by coronary diseases (10%) and among 
acute myocardial infarct survivors aged less than 60 (11.3%) 
(Gaddi et al 1999). This percentage increases to 40% when 
all the myocardial infarct survivors are considered without 
age limits (De Bruin et al 1996).
Prevalence estimates, on the other hand, strongly 
depend on the diagnostic criteria adopted; applying the 
most accepted ones to the free-living adult cohort of the 
Brisighella Heart study, we estimated a 2.8% prevalence 
of FCH, although some patients with metabolic syndrome 
or random association of other genetic factors may have 
contributed to prevalence overestimation (Cicero et al 1999). 
From data obtained on 1190 Japanese children a prevalence 
of 0.4% was calculated, suggesting that at least half of all 
individuals with FCH already demonstrate hyperlipidemia 
in childhood (Iwata et al 2003).
No other differences are apparent, but geographical 
distribution is not known, since the main studies carried out 
so far consist only of Caucasian patients living in Europe 
or in the US.
According to a conservative estimate (whole population: 
0–99 years), over 3.5 million subjects are affected by this 
disorder in EU (and 2.7 million in the US); it is the cause 
of approximately 30,000–70,000 infarcts/year in the EU 
(and more or less the same number in US), often premature 
(Gaddi et al 1999).
Because of the lack of agreement among researchers, 
and because of the intrinsic characteristics of the disease to 
appear in different moments with different phenotypes, it is 
often hard to obtain good epidemiological data on its real 
prevalence and to distinguish FCH from the metabolic syn-
drome and from patients with random clustering of genetic 
factors simulating the FCH phenotypes.
Clinical aspects
A high degree of diagnostic uncertainty exists in the catego-
rization as normal or abnormal of members of FCH kindred 
(Aguilar Salinas et al 2004). This observation was clearly Vascular Health and Risk Management 2007:3(6) 880
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conﬁ  rmed by a recent 5-year follow-up study showing how 
up to 40% of patients can be misclassiﬁ  ed based on a single 
observation (Veerkamp et al 2002). Different diagnostic 
criteria would result in conﬂ  icting results. This is a critical 
issue: depending on the diagnostic criteria used, completely 
different conclusions could result from the linkage analysis in 
the FCH studies (del Rincon Jarero et al 2002). Recently, an 
interesting nomogram for FCH detection has been proposed 
by Veerkamp et al (2004).
The nomogram is easy to use especially for general prac-
titioners, even if some concerns about its wide applicability 
are that in FCH, by deﬁ  nition, the values of TG and TC are 
strongly variable (in long, medium, and short periods); thus 
a ﬁ  xed percentile cut-off may be difﬁ  cult to use. Moreover, 
we have no data on periodical prevalence of the disease to 
elaborate a mixed time-percentile index. Then, percentiles 
of cholesterolemia and triglyceridemia are not available for 
all populations and the use of speciﬁ  c values different from 
those suggested for diagnosis and therapy for the general 
US/EU population (IAS 2003) may be really confounding 
for physicians. Using percentiles or nomograms, a high 
diagnostic overlap with other genetic hyperlipidemias may 
also occur, mainly due to the exclusion of the lipid phenotype 
variability as a main diagnostic criterion of FCH that could 
over-estimate the FCH prevalence in the population.
Another problem to be considered is that the labora-
tory manifestation of FCH could remain relatively silent 
until some events occur. In particular body weight increase 
appears to be strongly related to lipid modiﬁ  cation that could 
be observed in FCH patients (Koprovikova et al 2006). In 
fact, waist-to-hip ratio appears to be the best determinant of 
hyperlipidemia, particularly hypertriglyceridemia in FCH 
patients (van der Kallen et al 2004). This is particularly 
evident in children affected by FCH (ter Avest et al 2007a) 
and it could be related to insulin resistance (Veerkamp et al 
2005), and decreased plasma levels of adiponectin (van de 
Vleuten et al 2005a) and decreased levels of leptin (van de 
Vleuten et al 2005b).
FCH diagnosis is very complex in children, too, because 
of the lack of long-term data linking lipid values measured 
before 12 years to the expression of the disease in the adult 
state or in the old people. In any case, for children, too, 
Kuromori et al (2002) suggested avoiding cut-off points based 
on a given percentile, and suggested clarifying the family 
history and measuring lipid proﬁ  les in the parents (Kuromori 
et al 2002). Hyperapo B in children may be a precursor of 
other lipid abnormalities, and thus it suggested as a good 
marker of early diagnosis of FCH (Kuromori et al 2002).
In the present revision of the diagnostic criteria, we take 
into account that: (1) recent data indicate that “specialists 
try to ‘pull’ cases toward their specialty” (Hashem et al 
2003), causing an impressive number of severe diagnostic 
medical errors; (2) in the long-life asymptomatic phase 
of FCH (before CHD) the diagnosis might be strongly 
underestimated; (3) as far as possible, the diagnostic cut-off 
points should be identical to those suggested for risk strati-
ﬁ  cation in the general population, at least for Caucasians; 
and, (4) laboratory diagnostic methods should be easy, not 
expensive, and easily reproducible.
The following considerations are discussed:
Inherited hyperlipoproteinemia (LDL-C  160 mg/
dL and/or TG  200 mg/dL)
Often in FCH the HDLs are reduced (40 mg/dL); yet we do 
not have sufﬁ  cient evidence to suggest the use of this parameter 
in FCH diagnosis (De Bruin et al 1996). The LDL-C and TG 
cut-offs are also the “normal” limits suggested by the more 
recent report of the National Cholesterol Education Program 
(NCEP ATPIII) (Adult Treatment Panel III 2001). It is evident 
that the higher the number of samples taken and of family 
members studied, the better the diagnostic sensitivity and 
speciﬁ  city. It can be estimated that around 20% of the adult 
population will have values above these cut-off points; but the 
percentage drops to around 3% when both parameters (LDL-C 
and TG) are considered together and secondary hyperlipopro-
teinemias are excluded, and to even lower levels if the evalu-
ation of the intra-individual variability over a period of time 
and intrafamilial variability are included. The ﬁ  nal estimates 
(1%–2%) correspond to the estimated prevalence of FCH in 
the adult population (Cicero et al 1999).
Hyperlipoproteinemia B
High plasma level of apo B (125 mg/dL) is one of the best 
diagnostic and prognostic factor for FCH adults (Demacker 
et al 2000; Sniderman et al 2002; de Graaf et al 2004), and 
for children (Kuromori et al 2002; Sveger and Nordborg 
2004). Therefore, dosing with plasma lipid is required 
where specialized laboratories are available. However, in 
many countries the apoB dosage is not standardized and 
often not widely available, except where highly specialized 
laboratories are available: this is the reason it is reasonable 
to reserve the dosage of apoB to a second level diagnosis 
in specialized Lipid Clinics. Moreover, the most correct 
approach to indicate a diagnostic cut-off point is to choose 
a speciﬁ  c percentile of each considered laboratory value 
for that population. Therefore, there is still a large lack of Vascular Health and Risk Management 2007:3(6) 881
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epidemiological data on plasma apo B distribution in different 
populations and age classes, so that its interpretation in not 
easy nor univocal for the non specialist physician.
Primitive variability of the lipid phenotype
The propositus could present hypercholesterolemia, hypertri-
glyceridemia, both, or even a “normal” phenotype at different 
times. The variability is rarely fast, and could be observed 
only during a long observational phase (several months) 
(Delawi et al 2005). Because both LDL-C and TG are not 
necessarily high in FCH patients, it is plausible that values 
considered as borderline high by the ATP III guidelines 
(LDL-C  130 mg/dL and/or TG  150 mg/dL) (Durrington 
2004) could be useful to evaluate the intra-individual vari-
ability of the lipid phenotype. The propositus could even have 
a constant phenotype (mainly IIb phenotype), and family 
members could have a different phenotype (ie, an isolated 
rise in LDL-C or in TG plasma level) (Ylitalo et al 2002). If 
patients are already treated with antihyperlipidemic drugs, 
it could be necessary to give conﬁ  dence to the pre-treatment 
values (if available). However, to the best of our knowledge, 
no antihyperlipidemic treatment is able to stabilize the lipid 
phenotype variability of FCH patients, so that it is maintained 
if the drug dosage is stable.
Biomarkers of early atherosclerosis
Increased carotid artery intima-media thickness (IMT) was 
recently proposed as an adjunctive diagnostic parameter, 
able to distinguish better between affected and non-affected 
members in the same family (Ylitalo et al 2002). The strength 
of association is obviously higher if we observe patients already 
affected by an early coronary or cerebrovascular event or with 
a family history of early cardiovascular events. Members of 
FCH families showed impaired FMD, which was independently 
associated with markers of insulin resistance (Karasek et al 
2006). The group of De Graaf, historically involved in research 
on FCH, recently also demonstrated that FCH patients have 
also increased pulse wave velocity and reduced ﬂ  ow mediated 
dilation, both markers of arterial stiffness and endothelial dys-
function. However, the same group showed that adding these 
parameters to the traditional stratiﬁ  cation of cardiovascular 
risk did not increase the prediction ability, so they raised some 
doubts about the diagnostic utility of endothelial dysfunction 
markers in conditions such as FCHL a priori characterized by an 
elevated cardiovascular disease risk (Ter Avest et al 2007b, c). 
Some laboratory parameters have been also proposed, but until 
now no one has demonstrated a speciﬁ  c biomarker for FCH. 
Further research is needed in this ﬁ  eld.
Other clinical features
The correlation between fatty liver and non-alcoholic steato-
hepatitis (NASH) and metabolic disorders of triglycerides, 
LDL-C, and insulin resistance is well known, and is very 
complex (Sveger et al 2004). NASH prevalence is higher 
particularly in patients with metabolic syndrome (Green 
2003). Recently, De Bruin et al (2004) reported the presence 
of non-alcoholic fatty liver also in patients with FCH. At 
present, this important clinical ﬁ  nding is not useful for FCH 
diagnosis or for differential diagnosis (see later). Xantho-
matous phenomena are very rare in this disorder (Kane et al 
1989), although other simultaneous anomalies, such as the 
presence of peroxides in LDL and high Lp(a) plasma concen-
trations, could represent a triggering factor in the expression 
of xanthomatosis in sporadic cases (Mancuso et al 1996).
In the setting of general medicine, the following diag-
nostic criteria are thus suggested for FCH:
First level diagnosis
1)  In the patient: primary hyperlipoproteinemia (LDL-C 
 160 mg/dL and/or TG  200 mg/dL), PLUS
2)  In the patient and in at least one member of the family: 
primary variability of the lipid phenotype (hypercho-
lesterolemia, hypertriglyceridemia, both, or even a 
“normal” phenotype) evaluated on the basis of at least 3 
consecutive (bimonthly) controls (the repetition of lipid 
analysis before to deﬁ  ne a diagnosis of dyslipidemia is 
in agreement with the international guidelines) (Adult 
Treatment Panel III 2001).
Second level diagnosis (specialized labs only)
1)  Evaluation of apo B100 plasma level: preferably by stan-
dardized immunoturbidimetric assay (NHANES Group 
1994)
2)  Detection of small and dense LDL particles (LDL pat-
tern B): there is not yet a standardized method to dose 
small dense LDLs; different methods have been tested 
(from preparative and non-equilibrium density gradient 
ultracentifugation to nuclear magnetic resonance) but the 
most frequently used is the gradient gel electrophoresis 
(Rizzo and Berneis 2006)
3) Genetic tests to exclude similar more rare forms of 
familial dyslipidaemias, when indicated (unclear situa-
tions, suggestive clinical and laboratory condition)
Speciﬁ  c cases
If family data are not available, the presence of unexplained 
(primary) IIb phenotype (eg, not related to signiﬁ  cant change 
in dietary habits or body-weight gain or by an evident double Vascular Health and Risk Management 2007:3(6) 882
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heterozygosis for familial hypercholesterolemia and familial 
hypertriglyceridemia) may suggest the diagnosis (Gaddi et al 
1999). The presence of early onset atherosclerosis (IMT 
included) and/or clinical complications (CHD/CVD/POAD) 
in the patient and/or in relatives (probably carriers of the dis-
ease on the basis of genealogical tree) is not strictly diagnostic 
of FCH, but it could suggest an aggressive dyslipidemia 
or, in any case, a condition at high risk of cardiovascular 
disease. Lipid abnormalities (including presence of small 
and dense LDL) in non-controlled diabetes will be regarded 
with caution and have to be re-evaluated after improvement 
of diabetes control.
Differential diagnosis against 
metabolic syndrome
The recent enlargement of diagnostic criteria for metabolic 
syndrome (MS) proposed by the third report of the National 
Cholesterol Education Program (NCEP) expert panel on 
detection, evaluation, and treatment of high blood cholesterol 
(Adult Treatment Panel III 2001) has caused a signiﬁ  cant 
overlap with the diagnosis of FCH. MS was identiﬁ  ed in 65% 
of FCH patients compared with 19% in controls without FCH 
(odd ratio: 3.3, p  0.0001). The increased prevalence of the 
MS alone could account for a signiﬁ  cant part of the elevated 
CHD risk associated with FCH (Hopkins et al 2003) as well 
as the high prevalence of FCH among patients diagnosed, as 
MS produces an overestimate of CHD-risk in MS.
Common features between the two pathological condi-
tions are:
  -   Frequent hypertriglyceridemia and/or low plasma 
HDL-C level
  -   Frequent association with non-lipid cardiovascular 
risk factors as blood hypertension, abdominal obesity, 
reduced glucose tolerance/diabetes
  - Strongly increased cardiovascular disease risk
The main differences between the two conditions are:
  -  Apo B is constantly high in FCH, but not in MS. LDL-C 
values are usually normal or rather low in MS.
  -   The lipid phenotype is more variable in FCH than in 
MS (both in individuals and families)
  -   The inheritance of the disorder is much more evident 
in FCH, and life style is much less relevant on FCH 
clinical manifestation and prognosis than on MS
  -   Earlier clinical and laboratory manifestation in FCH 
than in MS
  -   Low grade inﬂ  ammation (eg, high plasma level of 
hsCRP, adhesion molecules) and/or procoagulative 
conditions (eg, high plasma level of ﬁ  brinogen, PAI-1) 
have been more frequently associated with MS (Gaddi 
and Cicero 2006)
The clinical picture and associated complications/condi-
tions (atherosclerosis, NASH, diabetes, hypertension) are not 
useful for differential diagnosis. In particular, overweight 
and insulin-resistance, that are main factors involved in the 
pathogenesis of MS, are strongly associated to the plasma 
lipid change observed in FCH patients (de Graaf et al 2004; 
Veerkamp et al 2005).
Recently, Ayyobi and Brunzell (2003) suggested that 
severe lipid abnormalities are more frequently caused by 
FCH rather than by diabetic hyperlipidemia or MS. This is 
a simpliﬁ  ed point of view that does not take into account the 
typical phenotypic variation of FCH, which also determines 
a wide range variation of laboratory parameters, from very 
high to very low levels. Moreover, also in non-controlled 
diabetes and in patients with multiple-causes of hyperlipo-
proteinemia (example: insulin-resistance syndrome plus ε4 
homozygous or heterozygous plus LPL deﬁ  cit) lipid values 
may rise to very high levels.
The marked variability of lipid proﬁ  le, not explained 
by diet or body-weight variations, might represent the best 
diagnostic criterion to reduce the overlapping between MS 
and FCH. Severity of lipid alteration, constant presence of 
pattern B LDL, and/or of high apo B plasma level (favoring 
FCH diagnosis), or presence of abdominal obesity and insu-
lin resistance (favoring MS) could orientate the differential 
diagnosis, but do not prove it.
As already above stated, lacking a speciﬁ  c laboratory 
or clinical marker of FCH, the ﬁ  nal diagnosis in patients 
with MS features could be often difﬁ  cult, especially in 
those subjects with insufﬁ  cient laboratory documentation, 
already taking antihyperlipidaemic drugs, and/or diabetics. 
However, from a practical point of view, if patient is diabetic 
the differential diagnosis with FCH could not be so relevant, 
because diabetic patients have to be already treated to reduce 
to the minimal level their cardiovascular disease risk inde-
pendently from the baseline plasma lipid (American Diabetes 
Association 2006). Therefore, in these patients it remains 
relevant to adequately monitor the plasma lipid level of the 
younger non-diabetic family member in order to eventually 
diagnose FCH early.
Prognosis
FCH is deﬁ  nitively very frequent in patients affected by 
CHD. In the general population, the spontaneous variability 
of lipid phenotype appears to be associated with an increased 
risk of cardiovascular disease (Cicero et al 2000). Until now, Vascular Health and Risk Management 2007:3(6) 883
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no adequately designed trials on FCH patients have been 
carried out to estimate their peculiar cardiovascular disease 
risk. Some authors suggest that it is at least as elevated as 
that of heterozygous familial hypercholesterolemia patients 
(Skoumas et al 2006). FCH is clearly also a risk factor for 
increased carotid artery intima-media thickness (IMT): the 
increased IMT observed in FCH patients corresponds, on 
average, to a 7-year increase in IMT (Keulen et al 2002). 
The parameter best correlated with IMT is the plasma apo 
B level and consequently the LDL particle size (but not 
LDL susceptibility to oxidation) (Liu et al 2002). A worse 
prognostic factor appears to be the constant association of 
hypercholesterolemia to hypertriglyceridemia: young people 
with this kind of lipid phenotype have a reduced coronary 
ﬂ  ow reserve during hyperemia compared with age-matched 
hypercholesterolemic not hypertriglyceridemic subjects 
(Pitkanen et al 1999). Hypertriglyceridemia per se appears in 
fact to be a signiﬁ  cant predictor of cardiovascular disease in 
proportion to the baseline TG levels (Austin et al 2000).
We suggest considering FCH patients at very high CHD 
and CVD risk, as conﬁ  rmed by family studies (Goldstein et al 
1973; Sniderman et al 2002; Ayyobi and Brunzell 2003); 
speciﬁ  cally, it is necessary to point out that risk estimates 
based on risk charts, scores, or functions used in the general 
population, probably grossly underestimate the real risk of 
the FCH patient, and must be avoided.
FCH patients management: 
practical guidelines
The main ﬁ  rst-line vascular diagnostic approach to be con-
sidered is the carotid ultrasound with morphometric evalu-
ation of the lesions, because it is highly predictive of future 
cardio- and cerebro-vascular events, and is inexpensive, not 
invasive, and easily repeatable (O’Leary and Polak 2002). 
IMT/ultrasound examination should also be performed, 
when possible, on other districts (aorta, ileo-femoral arter-
ies, etc). The control of silent myocardial ischemia could 
be performed with the same diagnostic ﬂ  ow chart recently 
suggested for familial heterozygous hypercholesterolemias 
(Civeira 2004); diagnostic algorithms speciﬁ  c for FCH are 
not yet available.
With regard to drug therapy, some small clinical trials 
have been conducted on patients deﬁ  ned as affected by “com-
bined” or “mixed” hyperlipoproteinemia (Forster et al 2002; 
Wang et al 2003; Grundy et al 2005). Other small trials con-
ducted on subjects selected as being affected by FCH suggest 
some efﬁ  cacy of statin (Blanco-Colio et al 2004; Sirtori et al 
2005), ﬁ  brates (Bredie et al 1996), omega 3 polyunsaturated 
fatty acids (Tato et al 1993), and thiazolidinediones (Abbink 
et al 2006) on secondary outcomes (eg, endothelial function, 
LDL composition, oxidation markers, inﬂ  ammation mark-
ers). Atorvastatin and fenoﬁ  brate displayed comparable 
efficiency in decreasing oxysterols, but they decreased 
lipid-corrected alpha-tocopherol levels in plasma, which 
are already low in FCH patients (Arca et al 2007). However 
a full-dosage of a powerful statin such as rosuvastatin was 
not able to improve endothelial function of FCH patients 
(ter Avest et al 2005). Moreover, pioglitazone 30 mg/day in 
patients on conventional lipid-lowering therapy acts favor-
ably on several metabolic parameters, such as TG/HDL 
(atherogenic index of plasma [–32.3%, p = 0.002], plasma 
glucose [–4.4%, p = 0.03], alanine-aminotransferase [ALT] 
[–7.7%, p = 0.005], and adiponectin [130.1%, p = 0.001]) 
(Thomas et al 2007). Thus, lacking speciﬁ  c long-term data 
on drug efﬁ  cacy on strong outcomes of FCH patients, the 
main proposed recommendations for FCH therapy are based 
on the results obtained from long-term clinical trials with 
hard outcomes on cardiovascular morbidity and mortality. 
However, the majority of available trial analyses are on the 
same group of patients with FCH, with mixed/multigenic 
hyperlipoproteinemia (from random association of different 
genetic factors in the same subjects), metabolic syndrome, 
secondary hyperlipoproteinemia, etc, and data obtained 
might be not strictly representative of the effect of tested 
drugs/lifestyle changes on FCH patients.
In any case, the effectiveness of statins to reduce cardio-
vascular risk suggests that these drugs should be the ﬁ  rst-line 
treatment for FCH also (Bays and Stein 2003), perhaps with 
a preference for those with a stronger triglyceride-lowering 
activity (Verseyden et al 2004). The triglyceride-lowering 
effect, which is mainly through an increase in the hepatic 
reuptake of VLDL, ILDL, and LDL is, however, less than 
that of ﬁ  brates, which increase lipoprotein lipase activity by 
a mechanism involving peroxisome proliferators activator 
receptors alpha and gamma (Insua et al 2002).
The ﬁ  brates’ cholesterol-lowering effect is, however, 
smaller than that of statins. Omega-3 polyunsaturated fatty 
acids also lower VLDL triglycerides, slightly increasing 
LDL-C and HDL-C (Calabresi et al 2004). The association of 
statins with drugs more active on TG plasma levels (omega-3 
polyunsaturated fatty acids, ﬁ  brates, nicotinic acid) could be 
an efﬁ  cacious way to treat this kind of patients (Grundy et al 
2005; Koh et al 2005). Ezetimibe, a selective inhibitor of the 
bowel cholesterol adsorption, might be an optimal drug to 
be associated to statins or ﬁ  brates instead of the prescribed 
resins (Jeu and Cheng 2003).Vascular Health and Risk Management 2007:3(6) 884
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Slow-release nicotinic acid is another very interesting 
and plausible therapeutic weapon to be associated to the 
standard statin and/or to ﬁ  brate therapy (Elam et al 2000); 
probably, the dose-dependent effects of nicotinic acid deriva-
tives and the good safety and interaction proﬁ  les, will open 
a new therapeutic approach even for more severe (and drug-
resistant) FCH patients.
In the absence of data on long-term effects of different 
therapies on the prognosis of FCH patients we suggest: (a) 
monitoring the therapy not only by lab tests, but also by 
evaluating IMT and other instrumental and clinical markers 
of CHD, and (b) following the theory of “the lower, the 
better”, treating these patients in order to reduce their cho-
lesterolemia and triglyceridemia to the best goals suggested 
by the international guidelines for cardiovascular diseases 
prevention (Adult Treatment Panel III 2001), in associa-
tion with a rigid control of all associated risk factors. The 
practitioner has to be advised that escape phenomena and 
variability of lipid phenotype might represent a major source 
of bias in analyzing the efﬁ  cacy of therapy.
The high prevalence of FCH and MS in the US and EU 
suggests that the ﬁ  rst-level diagnosis and the basic therapeutic 
strategy have to be prescribed by family physicians and/or by 
wide spread territorial specialized units. In this context, we 
think that the above suggestions, combined with the widely 
known recommendations of the ATP III (Adult Treatment 
Panel III 2001), will help easier early detection of patients 
likely to be diagnosed with FCH and of patients in general 
at high risk of cardiovascular disease.
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